Tissue 2-Hydroxyglutarate as a Biomarker for Isocitrate Dehydrogenase Mutations in Gliomas.
Hao-Wen SimRomina NejadWenjiang ZhangFarshad NassiriWarren MasonKenneth D AldapeGelareh ZadehEric X ChenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Our study demonstrates that rRS is a reliable biomarker of IDH mutation status. This technique can be used to determine IDH mutation status intraoperatively, and to guide treatment decisions based on IDH mutation status in real time. Finally, rRS values may provide additional prognostic information and further validation is required.
Keyphrases